AccurEdit Therapeutics, a Suzhou-based gene editing startup, raised $75 million in a Series A round to advance CRISPR-based programs toward the clinic. The financing ranks among the larger Chinese rounds for gene-editing companies and will fund preclinical development and IND-enabling studies. AccurEdit’s platform focuses on CRISPR modalities tailored for therapeutic safety and delivery in multiple indications. The raise demonstrates continued investor interest in next-generation genome editing despite global regulatory and manufacturing headwinds. Investors backing the round—unnamed in the filing—are betting on China-originated gene editing platforms to accelerate into local and global development pathways. The company said the proceeds will expand R&D capacity and accelerate lead candidate nomination, positioning AccurEdit to file regulatory submissions in China and potentially the U.S. as it scales.